Adicet Bio(us:ACET)

    0.8832

    -2.95%

    Updated on 2024-12-23

    Open:0.9100
    Close:0.8832
    High:0.9100
    Low:0.8600
    Pre Close:0.9100
    Volume:385919.00
    Amount:341595.22
    Turnover:0.47%
    Shares:82.40M
    MarketCap:72.78M
    DateTotalTotal SharesTotal RatioNewIncreasedDecreased
    2024-06-30346910.01%010
    2024-03-311077471982590.93%324022
    2023-12-31923336757177.11%92841
    2023-09-301043524641681.76%133043
    2023-06-301223670795185.24%182662
    2023-03-311243896900190.72%262653
    2022-12-311244203348197.86%253153
    2022-09-301194151824497.03%204340
    dateorgNametotalratiochangeShareschangeRatio
    2024-03-31Orbimed Advisors Llc1144714013.93%312500037.55%
    2024-03-31Ra Capital Management, L.P.75410009.18%7541000
    2024-03-31Tang Capital Management Llc64074007.80%5531048631.14%
    2024-03-31Balyasny Asset Management L.P.61816717.52%6181671
    2024-03-31Rtw Investments, Lp41346315.03%0
    2024-03-31Millennium Management Llc41061705.00%2784583210.70%
    2024-03-31Morgan Stanley40673054.95%126849645.32%
    2024-03-31Goldman Sachs Group Inc40055874.87%397697413899.19%
    2024-03-31Blackrock Inc.33732324.11%119055754.55%
    2024-03-31Vanguard Group Inc31265783.81%144150385.55%

    About

    Adicet Bio, Inc. is a clinical stage biotechnology company, which engages in discovering and developing allogeneic gamma delta T cell therapies for cancer. It also focuses on developing a pipeline of “off-the-shelf” gamma delta T cells. The company was founded by Aya Jakobovits in November 2014 and is headquartered in Boston, MA.
    Address:131 Dartmouth Street,3rd floor

    Market Movers